Key highlights
- Phase 2 ADMIRATION trial of bosakitug (ATI-045) did not achieve its primary endpoint of EASI score change at Week 24
- Company confirmed robust target engagement and biomarker downregulation despite the clinical endpoint failure
- Initiated Phase 2b ALPHA trial for modzatinib in lichen planus with results expected in late 2027
- Plan to file an Investigational New Drug application for oral ITK inhibitor ATI-9494 in Q4 2026
- Scheduled initiation of a Phase 2b trial for bispecific antibody ATI-052 in eosinophilic esophagitis for Q1 2027
Phase 2 Clinical Trial Outcome
Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial, which evaluated the humanized anti-TSLP monoclonal antibody bosakitug for moderate-to-severe atopic dermatitis, did not achieve its primary or secondary endpoints. The study failed to show a statistically significant percent change from baseline in the Eczema Area and Severity Index (EASI) score at Week 24. While clinical endpoints were not met, pharmacodynamic data confirmed robust target engagement of TSLP and downregulation of biomarkers related to immune activation, including Th1, Th2, and Th17. The candidate was generally well tolerated, but the company will not proceed with current development plans for this specific indication.
Strategic Pivot to ITK Inhibitor Portfolio
- Initiation of the randomized, double-blind Phase 2b ALPHA trial for modzatinib in moderate-to-severe lichen planus
- Expectation of top-line results from the oral erosive lichen planus cohort of the ALPHA trial in the second half of 2027
- Completion of IND-enabling studies for ATI-9494, an oral ITK inhibitor, with a regulatory filing expected in Q4 2026
- Planned Phase 1 clinical program for ATI-9494 to include single and multiple ascending doses followed by a proof-of-concept portion
- Intent to launch a Phase 2b trial for ATI-052 targeting eosinophilic esophagitis in the first quarter of 2027
Management Perspective
“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone.”
Business and Financial Context
Aclaris Therapeutics is a Wayne, Pennsylvania-based clinical-stage biopharmaceutical firm focused on immuno-inflammatory diseases. With a market capitalization of $621.76 million, the company operates as a research-intensive entity, evidenced by its annual revenue of $7.83 million against ongoing clinical expenditures. The shift toward oral kinase inhibitors like modzatinib and ATI-9494 represents a transition toward differentiated mechanisms of action that may offer advantages over traditional biologics. Shareholders and analysts will likely focus on the series of clinical and regulatory milestones scheduled throughout 2027 as the primary drivers of future company valuation.
Down 8.0% since our story on 16 Nov: $3.92 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.48 |
|---|---|
| 20 Oct | $3.77 |
| 21 Oct | $3.81 |
| 22 Oct | $3.83 |
| 23 Oct | $3.75 |
| 26 Oct | $3.79 |
| 27 Oct | $3.79 |
| 28 Oct | $3.96 |
| 29 Oct | $3.99 |
| 30 Oct | $3.97 |
| 2 Nov | $3.80 |
| 3 Nov | $3.74 |
| 4 Nov | $3.68 |
| 5 Nov | $3.61 |
| 6 Nov | $3.90 |
| 9 Nov | $4.24 |
| 10 Nov | $4.15 |
| 11 Nov | $4.34 |
| 12 Nov | $4.00 |
| 13 Nov | $3.92 |
| 16 Nov | $3.60 |
Management commentary
“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone.”
| Share price | $3.92 |
|---|---|
| Market cap | $622M |
| Revenue (annual) | $8M |
| 1-month price change | +15.98% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Aclaris Therapeutics, Inc. announcing top-line results from its Phase 2 ADMIRATION trial and subsequent pipeline updates.
Track Aclaris Therapeutics, Inc. live
Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.

